Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease

William J. Sandborn, Edward Vincent Loftus, Jr, Jean Frederic Colombel, Kenneth A. Fleming, Frank Seibold, Henry A. Homburger, Boualem Sendid, Roger W. Chapman, William J. Tremaine, Debra K. Kaul, Jeannie Wallace, William S. Harmsen, Alan R. Zinsmeister, Stephan R. Targan

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Background: The sensitivity of assays for antineutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), and antipancreatic antibody (PAB) in different laboratories is unknown. Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown. Methods: An incidence cohort of 290 patients with IBD were offered participation in the study. Blood was obtained from 162 patients (56%) (83 with ulcerative colitis, 79 with Crohn's disease) who agreed to participate. ANCA was determined in five laboratories, ASCA in two laboratories, and PAB in one laboratory. Results: In ulcerative colitis, the sensitivity of ANCA determined in five laboratories varied widely, ranging from 0-63%. In Crohn's disease, the sensitivity of ASCA determined in two laboratories did not vary significantly, ranging from 39-44%; and the sensitivity of PAB determined in one laboratory was 15%. The optimal diagnostic usefulness was obtained from one laboratory where the positive predictive values of a positive ANCA assay combined with a negative ASCA assay for ulcerative colitis, and a negative ANCA combined with a positive ASCA for Crohn's disease, were 75% and 86%, respectively. Conclusions: In patients with IBD, the sensitivity of ANCA varied widely in different laboratories, whereas the prevalence of ASCA was similar. The positive predictive values of the ANCA assay combined with the ASCA assay for ulcerative colitis and Crohn's disease are high enough to be clinically useful.

Original languageEnglish (US)
Pages (from-to)192-201
Number of pages10
JournalInflammatory Bowel Diseases
Volume7
Issue number3
StatePublished - 2001

Fingerprint

Ulcerative Colitis
Antineutrophil Cytoplasmic Antibodies
Crohn Disease
Saccharomyces cerevisiae
Antibodies
Population
Inflammatory Bowel Diseases
Incidence

Keywords

  • Crohn's disease
  • Serologic disease markers
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sandborn, W. J., Loftus, Jr, E. V., Colombel, J. F., Fleming, K. A., Seibold, F., Homburger, H. A., ... Targan, S. R. (2001). Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflammatory Bowel Diseases, 7(3), 192-201.

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. / Sandborn, William J.; Loftus, Jr, Edward Vincent; Colombel, Jean Frederic; Fleming, Kenneth A.; Seibold, Frank; Homburger, Henry A.; Sendid, Boualem; Chapman, Roger W.; Tremaine, William J.; Kaul, Debra K.; Wallace, Jeannie; Harmsen, William S.; Zinsmeister, Alan R.; Targan, Stephan R.

In: Inflammatory Bowel Diseases, Vol. 7, No. 3, 2001, p. 192-201.

Research output: Contribution to journalArticle

Sandborn, WJ, Loftus, Jr, EV, Colombel, JF, Fleming, KA, Seibold, F, Homburger, HA, Sendid, B, Chapman, RW, Tremaine, WJ, Kaul, DK, Wallace, J, Harmsen, WS, Zinsmeister, AR & Targan, SR 2001, 'Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease', Inflammatory Bowel Diseases, vol. 7, no. 3, pp. 192-201.
Sandborn, William J. ; Loftus, Jr, Edward Vincent ; Colombel, Jean Frederic ; Fleming, Kenneth A. ; Seibold, Frank ; Homburger, Henry A. ; Sendid, Boualem ; Chapman, Roger W. ; Tremaine, William J. ; Kaul, Debra K. ; Wallace, Jeannie ; Harmsen, William S. ; Zinsmeister, Alan R. ; Targan, Stephan R. / Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. In: Inflammatory Bowel Diseases. 2001 ; Vol. 7, No. 3. pp. 192-201.
@article{e2d3ef85ffdc4d79a4bd1a7d1fcc8192,
title = "Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease",
abstract = "Background: The sensitivity of assays for antineutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), and antipancreatic antibody (PAB) in different laboratories is unknown. Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown. Methods: An incidence cohort of 290 patients with IBD were offered participation in the study. Blood was obtained from 162 patients (56{\%}) (83 with ulcerative colitis, 79 with Crohn's disease) who agreed to participate. ANCA was determined in five laboratories, ASCA in two laboratories, and PAB in one laboratory. Results: In ulcerative colitis, the sensitivity of ANCA determined in five laboratories varied widely, ranging from 0-63{\%}. In Crohn's disease, the sensitivity of ASCA determined in two laboratories did not vary significantly, ranging from 39-44{\%}; and the sensitivity of PAB determined in one laboratory was 15{\%}. The optimal diagnostic usefulness was obtained from one laboratory where the positive predictive values of a positive ANCA assay combined with a negative ASCA assay for ulcerative colitis, and a negative ANCA combined with a positive ASCA for Crohn's disease, were 75{\%} and 86{\%}, respectively. Conclusions: In patients with IBD, the sensitivity of ANCA varied widely in different laboratories, whereas the prevalence of ASCA was similar. The positive predictive values of the ANCA assay combined with the ASCA assay for ulcerative colitis and Crohn's disease are high enough to be clinically useful.",
keywords = "Crohn's disease, Serologic disease markers, Ulcerative colitis",
author = "Sandborn, {William J.} and {Loftus, Jr}, {Edward Vincent} and Colombel, {Jean Frederic} and Fleming, {Kenneth A.} and Frank Seibold and Homburger, {Henry A.} and Boualem Sendid and Chapman, {Roger W.} and Tremaine, {William J.} and Kaul, {Debra K.} and Jeannie Wallace and Harmsen, {William S.} and Zinsmeister, {Alan R.} and Targan, {Stephan R.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "192--201",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease

AU - Sandborn, William J.

AU - Loftus, Jr, Edward Vincent

AU - Colombel, Jean Frederic

AU - Fleming, Kenneth A.

AU - Seibold, Frank

AU - Homburger, Henry A.

AU - Sendid, Boualem

AU - Chapman, Roger W.

AU - Tremaine, William J.

AU - Kaul, Debra K.

AU - Wallace, Jeannie

AU - Harmsen, William S.

AU - Zinsmeister, Alan R.

AU - Targan, Stephan R.

PY - 2001

Y1 - 2001

N2 - Background: The sensitivity of assays for antineutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), and antipancreatic antibody (PAB) in different laboratories is unknown. Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown. Methods: An incidence cohort of 290 patients with IBD were offered participation in the study. Blood was obtained from 162 patients (56%) (83 with ulcerative colitis, 79 with Crohn's disease) who agreed to participate. ANCA was determined in five laboratories, ASCA in two laboratories, and PAB in one laboratory. Results: In ulcerative colitis, the sensitivity of ANCA determined in five laboratories varied widely, ranging from 0-63%. In Crohn's disease, the sensitivity of ASCA determined in two laboratories did not vary significantly, ranging from 39-44%; and the sensitivity of PAB determined in one laboratory was 15%. The optimal diagnostic usefulness was obtained from one laboratory where the positive predictive values of a positive ANCA assay combined with a negative ASCA assay for ulcerative colitis, and a negative ANCA combined with a positive ASCA for Crohn's disease, were 75% and 86%, respectively. Conclusions: In patients with IBD, the sensitivity of ANCA varied widely in different laboratories, whereas the prevalence of ASCA was similar. The positive predictive values of the ANCA assay combined with the ASCA assay for ulcerative colitis and Crohn's disease are high enough to be clinically useful.

AB - Background: The sensitivity of assays for antineutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), and antipancreatic antibody (PAB) in different laboratories is unknown. Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown. Methods: An incidence cohort of 290 patients with IBD were offered participation in the study. Blood was obtained from 162 patients (56%) (83 with ulcerative colitis, 79 with Crohn's disease) who agreed to participate. ANCA was determined in five laboratories, ASCA in two laboratories, and PAB in one laboratory. Results: In ulcerative colitis, the sensitivity of ANCA determined in five laboratories varied widely, ranging from 0-63%. In Crohn's disease, the sensitivity of ASCA determined in two laboratories did not vary significantly, ranging from 39-44%; and the sensitivity of PAB determined in one laboratory was 15%. The optimal diagnostic usefulness was obtained from one laboratory where the positive predictive values of a positive ANCA assay combined with a negative ASCA assay for ulcerative colitis, and a negative ANCA combined with a positive ASCA for Crohn's disease, were 75% and 86%, respectively. Conclusions: In patients with IBD, the sensitivity of ANCA varied widely in different laboratories, whereas the prevalence of ASCA was similar. The positive predictive values of the ANCA assay combined with the ASCA assay for ulcerative colitis and Crohn's disease are high enough to be clinically useful.

KW - Crohn's disease

KW - Serologic disease markers

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0034887447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034887447&partnerID=8YFLogxK

M3 - Article

C2 - 11515844

AN - SCOPUS:0034887447

VL - 7

SP - 192

EP - 201

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -